Targeting Metallo-β-Lactamases: Discovery of Novel Dihydro-Chromeno Pyrrole (dCPs) Derivatives for Combating Drug-Resistant Infections.

Authors

Pulkit Dhiman, Satyajeet Das, Arya B Narayanan, Ashish M Kanhed, Krishan G Thakur, Vinod D Chaudhari

Published in

Journal of medicinal chemistry. Volume 69. Issue 16. Pages 20015-20036. Aug 27, 2026.

Abstract

Clinically approved therapies have established that combining β-lactam antibiotics with β-lactamase inhibitors is an effective strategy to counter antibiotic resistance; however, infections caused by metallo-β-lactamase (MBL) producing bacteria remain a critical unmet medical need. Building on our previous efforts targeting clinically relevant MBLs, including New Delhi metallo-β-lactamase (NDM), Verona integron-encoded metallo-β-lactamase (VIM), and imipenemase (IMP), we report the design and synthesis of 40 novel dihydro-chromeno-pyrrole (dCP) derivatives using a scaffold-hopping approach. Several compounds displayed potent MBL inhibition and lead compounds 74 and 91 effectively restored the activity of mmeropenem and imipenem against carbapenem-resistant Gram-negative pathogens. Optimization efforts focused on improving ADME properties while maintaining potency, and lead compounds were further evaluated for their pharmacokinetic profiles. Docking studies revealed favorable binding interactions of inhibitors with MBL proteins, supporting and justifying the observed inhibitory activity. Overall, this study provides a robust framework for lead optimization and identifies promising candidates for preclinical development.

PMID:
42679144
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.